市場調查報告書
商品編碼
1029194

Alpha-1 抗胰蛋白□缺乏症治療的全球市場:行業趨勢、市場份額、市場規模、增長、機會、預測(2021-2026)

Alpha 1 Antitrypsin Deficiency Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2015 年至 2020 年,全球 alpha-1 抗胰蛋白□缺乏症治療市場規模呈現強勁增長。展望未來,市場預計在 2021 年至 2026 年間以 9.2% 的複合年增長率增長。

呼吸系統疾病的增加是推動市場增長的重要因素之一。此外,增強療法的激增正在推動市場增長。

診斷方法方面的各種技術進步以及 AAT 製造和純化創新工藝的開發也是增長的驅動因素。其他因素,如廣泛的研發活動和改善的醫療基礎設施,預計將進一步提振市場。

本報告探討了全球 alpha-1 抗胰蛋白□缺乏症治療市場,並提供了全面的信息,包括市場概況、市場分析、價格分析、競爭格局和公司概況。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球 Alpha-1 抗胰蛋白□缺乏症治療市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章市場細分:按治療類型

  • 增強療法
  • 支氣管擴張劑
  • 皮質類固醇
  • 氧療
  • 其他

第 7 章市場細分:按管理途徑

  • 腸外
  • 吸入
  • 口服

第 8 章市場細分:按最終用戶

  • 醫院
  • 專科診所
  • 其他

第 9 章市場細分:按地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場細分:按國家/地區

第 10 章 SWOT 分析

第11章價值鏈分析

第十二章波特五力分析

第十三章價格分析

第14章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • AstraZeneca PLC
    • Boehringer Ingelheim GmbH
    • CSL Limited
    • GlaxoSmithKline Plc
    • Grifols S.A.
    • Kamada Ltd.
    • LFB Biomedicaments
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: SR1020F144_Report

The global alpha 1 antitrypsin deficiency treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.

The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha 1 antitrypsin deficiency treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, route of administration and end user.

Breakup by Treatment Type:

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Others

Breakup by Route of Administration:

  • Parenteral
  • Inhalation
  • Oral

Breakup by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, Boehringer Ingelheim GmbH, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments, Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report:

  • How has the global alpha 1 antitrypsin deficiency treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alpha 1 antitrypsin deficiency treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alpha 1 antitrypsin deficiency treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alpha 1 Antitrypsin Deficiency Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Augmentation Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bronchodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Corticosteroids
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Oxygen Therapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Parenteral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Inhalation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca PLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Boehringer Ingelheim GmbH
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 CSL Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 GlaxoSmithKline Plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Grifols S.A.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Kamada Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 LFB Biomedicaments
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Treatment Type (in %), 2020
  • Figure 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Route of Administration (in %), 2020
  • Figure 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by End User (in %), 2020
  • Figure 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 9: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 10: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 11: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 12: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: North America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 31: North America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 32: United States: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 33: United States: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 34: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 35: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 36: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: China: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: China: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 41: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: India: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 43: India: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 44: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 45: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 46: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 47: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 48: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 49: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 50: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 51: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 52: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 53: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 54: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 55: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 56: France: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 57: France: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 58: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 59: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 60: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 61: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 62: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 63: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 64: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 65: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 66: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 67: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 68: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 69: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 70: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 71: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 72: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 73: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 74: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 75: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 76: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 77: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 78: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: SWOT Analysis
  • Figure 79: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Value Chain Analysis
  • Figure 80: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2021-2026
  • Table 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
  • Table 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by End User (in Million US$), 2021-2026
  • Table 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Structure
  • Table 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Players